시장보고서
상품코드
1309713

세계의 오피오이드 사용 장애(OUD) 시장 규모, 점유율, 산업 동향 분석 보고서 : 약품 등급별(부프레노르핀, 메타돈, 나르트렉손), 투여 경로별, 유통 채널별, 지역별 전망 및 예측(2023-2030년)

Global Opioid Use Disorder (OUD) Market Size, Share & Industry Trends Analysis Report By Drug Class (Buprenorphine, Methadone and Naltrexone), By Route of Administration, By Distribution Channel, By Regional Outlook and Forecast, 2023 - 2030

발행일: | 리서치사: KBV Research | 페이지 정보: 영문 204 Pages | 배송안내 : 즉시배송


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 오피오이드 사용 장애(OUD : Opioid Use Disorder) 시장 규모는 9.9%의 CAGR 규모로 성장하여 2030년 64억 달러 규모에 달할 것으로 예측됩니다.

그러나 이러한 약물은 근육통, 메스꺼움, 구토, 설사, 변비, 호흡기 장애, 뼈, 관절통, 방광통, 복부 경련 등을 자주 일으킵니다. 또한 약물 반응이 강한 경우, 환자는 우울증 및 기타 심리적 문제를 경험할 수 있습니다. 신체 의존성과 중독 임상적인 우려가 적절한 처방을 방해하고 통증 관리가 불충분해질 수 있습니다. 이러한 폐해는 시장 확대를 제한할 수 있습니다. COVID-19 유행은 수요에 따라 제약 회사에 유리하거나 불리하게 영향을 미쳤습니다. 병원이나 클리닉과 같은 의료 시설에 가는 위험을 감수하는 사람이 줄어들어 일부 의약품은 수요가 감소했습니다. 각 정부는 바이러스 확산을 막기 위해 전국적으로 엄격한 봉쇄 조치를 실시했습니다. COVID-19와 관련된 혼란 결과, 매출은 급격히 감소했습니다. 그 결과, 유행 기간 동안 세계의 경제는 쇠퇴 경향을 보였습니다.

약물 등급 전망

마약에 따라 시장은 부프레놀핀, 메타돈, 나르트렉손으로 분류됩니다. 2022년 부프레노르핀 부문이 가장 큰 수익 점유율을 차지하여 시장을 독점했습니다. 시장은 부프레놀핀 패치 치료 수요가 증가하고 있습니다. 이러한 패치는 오피오이드 사용 장애를 치료하는 효율적인 치료법으로 간주됩니다. 경피 패치는 약물 전달 메커니즘 개선 및 통증 완화와 같은 몇 가지 일반적인 및자가 투여 혜택을 제공합니다. 이러한 경피 패치는 OUD를 위해 24시간 365일 오피오이드 투약이 필요한 사람의 대체 약물이기도 합니다. 서브로케이드, 서브퀴손, 서브솔브는 부프레놀핀의 중요 치료제입니다.

투여 경로 전망

투여 경로에 따라 시장은 경구제와 비경구제로 세분화되며 2022년 시장은 비경구 투여 부문이 가장 높은 판매 점유율을 차지합니다. 비경구 투여 방법은 칼로리를 보급하고 약물을 신속하게 전달하는 데 사용할 수 있습니다. 비경구 투여는 약물이 혈류에 신속하게 도달하기 때문에 작용 발현이 빠릅니다. 이것은 오피오이드 이탈 증상을 관리하고 OUD 환자를 즉시 구제하는 데 특히 중요합니다. 비경구 투여는 헬스케어 전문가가 약물을 투여하기 때문에 약물 사용이나 오용 위험을 최소화할 수 있습니다. 비경구 투여의 이러한 장점은 이 분야 시장 성장을 지원할 것으로 예상됩니다.

유통 채널 전망

유통 채널별로는 병원 약국, 소매 약국, 점포, 온라인 약국으로 분류됩니다. 온라인 약국 부문은 2022년 시장의 돌출한 수익 점유율을 예측했습니다. 이는 병원 및 기타 의료시설 전자 처방전 이용이 증가하고 있는 것 외에 인터넷 이용자 증가, 온라인 서비스 접근성 향상 등이 요인입니다. 온라인 약국 성장은 원격 진찰과 진단 지원 확대에 의해 촉진됩니다. 현재 온라인 약국 약을 구입할 때 사용할 수 있는 전자 처방전은 원격 진단을 통해 만들 수 있습니다.

지역별 전망

지역별로 시장은 북미, 유럽, 아시아태평양, LAMEA로 구분됩니다. 2022년 북미가 시장 가장 높은 수익 점유율을 획득하여 시장을 선도했습니다. 북미에서 가장 큰 수익 점유율에 영향을 미치는 주요 요인 중 하나는 미국과 캐나다 오피오이드의 유행입니다. 만연하고 있는 만성 질환은 통증 관리를 위한 오피오이드 사용량 증가의 주된 요인입니다. 이로 인해 OUD 유병률이 상승하고 이 지역 성장이 예상될 것으로 예상됩니다.

목차

제1장 시장 범위와 조사 방법

  • 시장 정의
  • 목적
  • 시장 범위
  • 세분화
  • 조사 방법

제2장 시장 주요 요약

  • 소개
    • 주요 요약
      • 시장 구성과 시나리오
  • 시장에 영향을 미치는 주요 요인
    • 시장 성장 촉진 요인
    • 시장 성장 억제 요인

제3장 오피오이드 사용 장애(OUD) 시장 전개되는 전략

제4장 세계의 오피오이드 사용 장애(OUD) 시장 : 약제 등급별

  • 세계의 부프레노르핀 시장 : 지역별
  • 세계의 메타돈 시장 : 지역별
  • 세계의 나르트렉손 시장 : 지역별

제5장 세계의 오피오이드 사용 장애(OUD) 시장 : 투여 경로별

  • 세계의 비경구약 시장 : 지역별
  • 세계의 구강 시장 : 지역별

제6장 세계의 오피오이드 사용 장애(OUD) 시장 : 유통 채널별

  • 세계의 병원 약국 시장 : 지역별
  • 세계의 소매 약국 및 점포 시장 : 지역별
  • 세계의 온라인 약국 시장 : 지역별

제7장 세계의 오피오이드 사용 장애(OUD) 시장 : 지역별

  • 북미
    • 북미 시장 : 국가별
      • 미국
      • 캐나다
      • 멕시코
      • 기타 북미
  • 유럽
    • 유럽 시장 : 국가별
      • 독일
      • 영국
      • 프랑스
      • 러시아
      • 스페인
      • 이탈리아
      • 기타 유럽
  • 아시아태평양
    • 아시아태평양 시장 : 국가별
      • 중국
      • 일본
      • 인도
      • 한국
      • 싱가포르
      • 말레이시아
      • 기타 아시아태평양
  • 라틴아메리카, 중동, 아프리카
    • 라틴아메리카, 중동, 아프리카 시장 : 국가별
      • 브라질
      • 아르헨티나
      • 아랍에미리트(UAE)
      • 사우디아라비아
      • 남아프리카
      • 나이지리아
      • 기타 라틴아메리카, 중동, 아프리카

제8장 기업 프로필

  • Indivior PLC(Reckitt Benckiser Group plc)
  • Collegium Pharmaceutical, Inc(BioDelivery Sciences International, Inc.)
  • Orexo AB(Orexo US, Inc)
  • Alkermes PLC
  • Titan Pharmaceuticals, Inc
  • Camurus AB
  • AstraZeneca PLC
  • Hikma Pharmaceuticals PLC
  • Mallinckrodt PLC
  • Viatris, Inc
NJH 23.08.24

The Global Opioid Use Disorder (OUD) Market size is expected to reach $6.4 billion by 2030, rising at a market growth of 9.9% CAGR during the forecast period.

Asia Pacific region healthcare sector is anticipated to rise due to the general public's increased knowledge of opioid disorders and the region's rising healthcare spending. Consequently, APAC registered $706.9 million revenue in the market in 2022. Growing elderly populations, increased public knowledge of healthcare services, and an increase in chronic diseases are all factors responsible for the growth. On the other hand, the Methadone Maintenance Treatment Program, a multifaceted therapy method that aims to reduce the health and social problem caused by drug diseases, was successfully implemented by the China' government to address the severe drug problem in China. Some of the factors impacting the market are expanding the use of buprenorphine patches in therapy, growing focus of non-governmental & governmental institutions for raising awareness, and OUD Drugs' negative effects.

The increasing use of buprenorphine patches as a successful treatment for opioid use disorder is one of the forthcoming trends in the market. One of the most cutting-edge methods for treating opioid use disorder is the use of buprenorphine patches. Transdermal patches are a more comfortable drug delivery method that successfully lowers pain and can be self-administered by the patient than traditional treatment techniques such as injections. A significant aspect that is fueling the market's growth is the increasing involvement of governmental and non-governmental groups in raising awareness about opioid overdose and its dangers. A number of groups have expanded their efforts to address the issue as a result of the sharp rise in the number of opioid addicts.

However, these medications frequently cause muscle aches, nausea, vomiting, diarrhea, constipation, respiratory problems, bone/joint pain, bladder pain, and abdominal cramping. In addition, when a drug reaction is strong, the patient may also experience depression and other psychological issues. Clinical concerns about physical dependence and addiction may hinder appropriate prescribing, resulting in insufficient pain management. These negative effects may limit the expansion of the market. The COVID-19 pandemic affected pharmaceutical firms in both favorable and negative manner, depending on demand. Certain pharmaceutical products saw decreased demand as fewer individuals risked going to healthcare facilities like hospitals and clinics. The respective governments implemented strict national lockdowns to stop the spread of virus from spreading. As a result of COVID-19-related disruptions, sales continued to decline sharply. As a result, during the pandemic, there was a declining tendency in the worldwide economy.

Drug Class Outlook

Based on drug, the market is classified into buprenorphine, methadone, and naltrexone. In 2022, the buprenorphine segment dominated the market with the maximum revenue share. The market witnessed a rise in demand for buprenorphine patch treatments. These patches are regarded as an efficient therapy for treating opioid use disorder. Transdermal patches have several common and self-administered benefits, including improving the mechanism of drug delivery and reducing pain. These transdermal patches can also be an alternative for people who need 24/7 opioid medication for OUD. SUBLOCADE, SUBOXONE, and ZUBSOLV are some crucial buprenorphine medications.

Route of Administration Outlook

On the basis of route of administration, the market is fragmented into oral, and parenteral. The parenteral segment held the highest revenue share in the market in 2022. The parenteral method can be used to supplement calories and deliver medications quickly. Parenteral administration allows for the drug to reach the bloodstream quickly, resulting in a rapid onset of action. This is particularly important in managing opioid withdrawal symptoms and providing immediate relief to individuals with OUD. The parenteral route can help minimize the risk of drug diversion and misuse since the medication is administered by healthcare professionals. These benefits of parenteral administration are predicted to support the market growth in this segment.

Distribution Channel Outlook

By distribution channel, the market is categorized into hospital pharmacies, retail pharmacies & stores, and online pharmacies. The online pharmacies segment projected a prominent revenue share in the market in 2022. This is attributed to the increasing usage of e-prescriptions at hospitals along with other healthcare facilities as well as the growth in internet users, increased accessibility to online services, and other factors. The growth of online pharmacy is also fueled by the expansion of teleconsultation and diagnostic support. Nowadays, e-prescriptions that can be used to buy medications from online pharmacies can be created through remote consultation.

Regional Outlook

Region wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the North America region led the market by generating highest revenue share in the market. One of the main factors influencing North America's most significant revenue share is the opioid epidemic in the United States and Canada. Chronic diseases, which are becoming increasingly prevalent, are the primary drivers of the rising usage of opioids for the management of pain. This is predicted to rise the prevalence of OUD, thereby offering growth prospects in the region.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Indivior PLC (Reckitt Benckiser Group plc), Collegium Pharmaceutical, Inc. (BioDelivery Sciences International, Inc.), Orexo AB (Orexo US, Inc.), Alkermes PLC, Titan Pharmaceuticals, Inc., Camurus AB, AstraZeneca PLC, Hikma Pharmaceuticals PLC, Mallinckrodt PLC, and Viatris, Inc.

Strategies Deployed in Opioid Use Disorder (OUD) Market

May-2023: Indivior PLC received approval from the U.S. Food and Drug Administration for OPVEE (nalmefene) nasal spray for the treatment of opioid overdose induced by natural or synthetic opioids. OPVEE contains nalmefene, an opioid receptor that delivers fast onset and long-duration reversal of opioid-induced respiratory depression.

May-2023: Camurus received approval from the US Food and Drug Administration (FDA) for its Brixadi (buprenorphine) extended-release injection for subcutaneous (SC) use, to treat moderate to severe opioid use disorder. The Brixadi would be used as a part of a complete treatment plan that includes counseling and psychosocial support.

Mar-2023: Indivior PLC took over Opiant Pharmaceuticals, Inc., a pharmaceutical company that develops treatments for drug overdose and addictions. The acquisition strengthens the addiction treatment and science portfolio of the company by adding Opiant's late-stage assets, notably OPNT003, an investigational opioid overdose treatment.

Jan-2023: Hikma Pharmaceuticals PLC revealed Naloxone Hydrochloride Injection, USP, 2mg/2mL, in the prefilled syringe (PFS) form. The drug is used to treat known or suspected opioid overdose. The launch expands the portfolio of addiction therapy treatments of the company.

Sep-2022: Orexo AB formed a partnership with Trinity Health, a comprehensive healthcare system. With this partnership, Trinity Health would offer Orexo's evidence-based digital therapies vorvida® and deprexis® to help patients manage depression and excessive drinking and expand patient access to digital therapeutics.

Jul-2022: Titan Pharmaceuticals, Inc. got approval for its Investigational New Drug ("IND") application from U.S. Food and Drug Administration ("FDA"), for the Phase 1 study of its subdermal formulation of nalmefene, an opioid antagonist which is to be used in the prevention of relapse following opioid detoxification in adults with Opioid Use Disorder ("OUD").

Jul-2021: AstraZeneca took over Alexion Pharmaceuticals, a global biopharmaceutical company. Through this acquisition, the company would be able to enter into medicines for rare diseases and the beginning of a new chapter. Further, the acquisition improved AstraZeneca's scientific presence in immunology and, through Alexion's new complement-biology platform and robust pipeline, would continue to pioneer the discovery & development of medicines for patients with rare diseases.

Jun-2021: U.S. Food and Drug Administration (FDA) has approved LYBALVI (olanzapine and samidorphan), an oral atypical antipsychotic of Alkermes plc, for the treatment of schizophrenia and bipolar I disorder.

Aug-2019: Orexo AB signed an agreement with GAIA AG, a health company that specializes in the development of eHealth and mHealth interventions. The agreement enables the company to have global commercial rights to the product. Both companies would leverage proven effective treatments and technology to bring new digital therapeutics products.

Jul-2019: Camurus AB signed a license agreement with Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, for the use of Camurus's proprietary FluidCrystal® (FC) technology in the development, manufacturing, and commercializing formulation of zilucoplan. The agreement enables the company to develop new promising product candidates based on our unique FluidCrystal® technology.

Scope of the Study

Market Segments covered in the Report:

By Drug Class

  • Buprenorphine
  • Methadone
  • Naltrexone

By Route of Administration

  • Parenteral
  • Oral

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies & Stores
  • Online Pharmacies

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled

  • Indivior PLC (Reckitt Benckiser Group plc)
  • Collegium Pharmaceutical, Inc. (BioDelivery Sciences International, Inc.)
  • Orexo AB (Orexo US, Inc.)
  • Alkermes PLC
  • Titan Pharmaceuticals, Inc.
  • Camurus AB
  • AstraZeneca PLC
  • Hikma Pharmaceuticals PLC
  • Mallinckrodt PLC
  • Viatris, Inc.

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Global Opioid Use Disorder (OUD) Market, by Drug Class
    • 1.4.2 Global Opioid Use Disorder (OUD) Market, by Route of Administration
    • 1.4.3 Global Opioid Use Disorder (OUD) Market, by Distribution Channel
    • 1.4.4 Global Opioid Use Disorder (OUD) Market, by Geography
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
      • 2.1.1.1 Market Composition and Scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Strategies Deployed in Opioid Use Disorder (OUD) Market

Chapter 4. Global Opioid Use Disorder (OUD) Market by Drug Class

  • 4.1 Global Buprenorphine Market by Region
  • 4.2 Global Methadone Market by Region
  • 4.3 Global Naltrexone Market by Region

Chapter 5. Global Opioid Use Disorder (OUD) Market by Route of Administration

  • 5.1 Global Parenteral Market by Region
  • 5.2 Global Oral Market by Region

Chapter 6. Global Opioid Use Disorder (OUD) Market by Distribution Channel

  • 6.1 Global Hospital Pharmacies Market by Region
  • 6.2 Global Retail Pharmacies & Stores Market by Region
  • 6.3 Global Online Pharmacies Market by Region

Chapter 7. Global Opioid Use Disorder (OUD) Market by Region

  • 7.1 North America Opioid Use Disorder (OUD) Market
    • 7.1.1 North America Opioid Use Disorder (OUD) Market by Drug Class
      • 7.1.1.1 North America Buprenorphine Market by Country
      • 7.1.1.2 North America Methadone Market by Country
      • 7.1.1.3 North America Naltrexone Market by Country
    • 7.1.2 North America Opioid Use Disorder (OUD) Market by Route of Administration
      • 7.1.2.1 North America Parenteral Market by Country
      • 7.1.2.2 North America Oral Market by Country
    • 7.1.3 North America Opioid Use Disorder (OUD) Market by Distribution Channel
      • 7.1.3.1 North America Hospital Pharmacies Market by Country
      • 7.1.3.2 North America Retail Pharmacies & Stores Market by Country
      • 7.1.3.3 North America Online Pharmacies Market by Country
    • 7.1.4 North America Opioid Use Disorder (OUD) Market by Country
      • 7.1.4.1 US Opioid Use Disorder (OUD) Market
        • 7.1.4.1.1 US Opioid Use Disorder (OUD) Market by Drug Class
        • 7.1.4.1.2 US Opioid Use Disorder (OUD) Market by Route of Administration
        • 7.1.4.1.3 US Opioid Use Disorder (OUD) Market by Distribution Channel
      • 7.1.4.2 Canada Opioid Use Disorder (OUD) Market
        • 7.1.4.2.1 Canada Opioid Use Disorder (OUD) Market by Drug Class
        • 7.1.4.2.2 Canada Opioid Use Disorder (OUD) Market by Route of Administration
        • 7.1.4.2.3 Canada Opioid Use Disorder (OUD) Market by Distribution Channel
      • 7.1.4.3 Mexico Opioid Use Disorder (OUD) Market
        • 7.1.4.3.1 Mexico Opioid Use Disorder (OUD) Market by Drug Class
        • 7.1.4.3.2 Mexico Opioid Use Disorder (OUD) Market by Route of Administration
        • 7.1.4.3.3 Mexico Opioid Use Disorder (OUD) Market by Distribution Channel
      • 7.1.4.4 Rest of North America Opioid Use Disorder (OUD) Market
        • 7.1.4.4.1 Rest of North America Opioid Use Disorder (OUD) Market by Drug Class
        • 7.1.4.4.2 Rest of North America Opioid Use Disorder (OUD) Market by Route of Administration
        • 7.1.4.4.3 Rest of North America Opioid Use Disorder (OUD) Market by Distribution Channel
  • 7.2 Europe Opioid Use Disorder (OUD) Market
    • 7.2.1 Europe Opioid Use Disorder (OUD) Market by Drug Class
      • 7.2.1.1 Europe Buprenorphine Market by Country
      • 7.2.1.2 Europe Methadone Market by Country
      • 7.2.1.3 Europe Naltrexone Market by Country
    • 7.2.2 Europe Opioid Use Disorder (OUD) Market by Route of Administration
      • 7.2.2.1 Europe Parenteral Market by Country
      • 7.2.2.2 Europe Oral Market by Country
    • 7.2.3 Europe Opioid Use Disorder (OUD) Market by Distribution Channel
      • 7.2.3.1 Europe Hospital Pharmacies Market by Country
      • 7.2.3.2 Europe Retail Pharmacies & Stores Market by Country
      • 7.2.3.3 Europe Online Pharmacies Market by Country
    • 7.2.4 Europe Opioid Use Disorder (OUD) Market by Country
      • 7.2.4.1 Germany Opioid Use Disorder (OUD) Market
        • 7.2.4.1.1 Germany Opioid Use Disorder (OUD) Market by Drug Class
        • 7.2.4.1.2 Germany Opioid Use Disorder (OUD) Market by Route of Administration
        • 7.2.4.1.3 Germany Opioid Use Disorder (OUD) Market by Distribution Channel
      • 7.2.4.2 UK Opioid Use Disorder (OUD) Market
        • 7.2.4.2.1 UK Opioid Use Disorder (OUD) Market by Drug Class
        • 7.2.4.2.2 UK Opioid Use Disorder (OUD) Market by Route of Administration
        • 7.2.4.2.3 UK Opioid Use Disorder (OUD) Market by Distribution Channel
      • 7.2.4.3 France Opioid Use Disorder (OUD) Market
        • 7.2.4.3.1 France Opioid Use Disorder (OUD) Market by Drug Class
        • 7.2.4.3.2 France Opioid Use Disorder (OUD) Market by Route of Administration
        • 7.2.4.3.3 France Opioid Use Disorder (OUD) Market by Distribution Channel
      • 7.2.4.4 Russia Opioid Use Disorder (OUD) Market
        • 7.2.4.4.1 Russia Opioid Use Disorder (OUD) Market by Drug Class
        • 7.2.4.4.2 Russia Opioid Use Disorder (OUD) Market by Route of Administration
        • 7.2.4.4.3 Russia Opioid Use Disorder (OUD) Market by Distribution Channel
      • 7.2.4.5 Spain Opioid Use Disorder (OUD) Market
        • 7.2.4.5.1 Spain Opioid Use Disorder (OUD) Market by Drug Class
        • 7.2.4.5.2 Spain Opioid Use Disorder (OUD) Market by Route of Administration
        • 7.2.4.5.3 Spain Opioid Use Disorder (OUD) Market by Distribution Channel
      • 7.2.4.6 Italy Opioid Use Disorder (OUD) Market
        • 7.2.4.6.1 Italy Opioid Use Disorder (OUD) Market by Drug Class
        • 7.2.4.6.2 Italy Opioid Use Disorder (OUD) Market by Route of Administration
        • 7.2.4.6.3 Italy Opioid Use Disorder (OUD) Market by Distribution Channel
      • 7.2.4.7 Rest of Europe Opioid Use Disorder (OUD) Market
        • 7.2.4.7.1 Rest of Europe Opioid Use Disorder (OUD) Market by Drug Class
        • 7.2.4.7.2 Rest of Europe Opioid Use Disorder (OUD) Market by Route of Administration
        • 7.2.4.7.3 Rest of Europe Opioid Use Disorder (OUD) Market by Distribution Channel
  • 7.3 Asia Pacific Opioid Use Disorder (OUD) Market
    • 7.3.1 Asia Pacific Opioid Use Disorder (OUD) Market by Drug Class
      • 7.3.1.1 Asia Pacific Buprenorphine Market by Country
      • 7.3.1.2 Asia Pacific Methadone Market by Country
      • 7.3.1.3 Asia Pacific Naltrexone Market by Country
    • 7.3.2 Asia Pacific Opioid Use Disorder (OUD) Market by Route of Administration
      • 7.3.2.1 Asia Pacific Parenteral Market by Country
      • 7.3.2.2 Asia Pacific Oral Market by Country
    • 7.3.3 Asia Pacific Opioid Use Disorder (OUD) Market by Distribution Channel
      • 7.3.3.1 Asia Pacific Hospital Pharmacies Market by Country
      • 7.3.3.2 Asia Pacific Retail Pharmacies & Stores Market by Country
      • 7.3.3.3 Asia Pacific Online Pharmacies Market by Country
    • 7.3.4 Asia Pacific Opioid Use Disorder (OUD) Market by Country
      • 7.3.4.1 China Opioid Use Disorder (OUD) Market
        • 7.3.4.1.1 China Opioid Use Disorder (OUD) Market by Drug Class
        • 7.3.4.1.2 China Opioid Use Disorder (OUD) Market by Route of Administration
        • 7.3.4.1.3 China Opioid Use Disorder (OUD) Market by Distribution Channel
      • 7.3.4.2 Japan Opioid Use Disorder (OUD) Market
        • 7.3.4.2.1 Japan Opioid Use Disorder (OUD) Market by Drug Class
        • 7.3.4.2.2 Japan Opioid Use Disorder (OUD) Market by Route of Administration
        • 7.3.4.2.3 Japan Opioid Use Disorder (OUD) Market by Distribution Channel
      • 7.3.4.3 India Opioid Use Disorder (OUD) Market
        • 7.3.4.3.1 India Opioid Use Disorder (OUD) Market by Drug Class
        • 7.3.4.3.2 India Opioid Use Disorder (OUD) Market by Route of Administration
        • 7.3.4.3.3 India Opioid Use Disorder (OUD) Market by Distribution Channel
      • 7.3.4.4 South Korea Opioid Use Disorder (OUD) Market
        • 7.3.4.4.1 South Korea Opioid Use Disorder (OUD) Market by Drug Class
        • 7.3.4.4.2 South Korea Opioid Use Disorder (OUD) Market by Route of Administration
        • 7.3.4.4.3 South Korea Opioid Use Disorder (OUD) Market by Distribution Channel
      • 7.3.4.5 Singapore Opioid Use Disorder (OUD) Market
        • 7.3.4.5.1 Singapore Opioid Use Disorder (OUD) Market by Drug Class
        • 7.3.4.5.2 Singapore Opioid Use Disorder (OUD) Market by Route of Administration
        • 7.3.4.5.3 Singapore Opioid Use Disorder (OUD) Market by Distribution Channel
      • 7.3.4.6 Malaysia Opioid Use Disorder (OUD) Market
        • 7.3.4.6.1 Malaysia Opioid Use Disorder (OUD) Market by Drug Class
        • 7.3.4.6.2 Malaysia Opioid Use Disorder (OUD) Market by Route of Administration
        • 7.3.4.6.3 Malaysia Opioid Use Disorder (OUD) Market by Distribution Channel
      • 7.3.4.7 Rest of Asia Pacific Opioid Use Disorder (OUD) Market
        • 7.3.4.7.1 Rest of Asia Pacific Opioid Use Disorder (OUD) Market by Drug Class
        • 7.3.4.7.2 Rest of Asia Pacific Opioid Use Disorder (OUD) Market by Route of Administration
        • 7.3.4.7.3 Rest of Asia Pacific Opioid Use Disorder (OUD) Market by Distribution Channel
  • 7.4 LAMEA Opioid Use Disorder (OUD) Market
    • 7.4.1 LAMEA Opioid Use Disorder (OUD) Market by Drug Class
      • 7.4.1.1 LAMEA Buprenorphine Market by Country
      • 7.4.1.2 LAMEA Methadone Market by Country
      • 7.4.1.3 LAMEA Naltrexone Market by Country
    • 7.4.2 LAMEA Opioid Use Disorder (OUD) Market by Route of Administration
      • 7.4.2.1 LAMEA Parenteral Market by Country
      • 7.4.2.2 LAMEA Oral Market by Country
    • 7.4.3 LAMEA Opioid Use Disorder (OUD) Market by Distribution Channel
      • 7.4.3.1 LAMEA Hospital Pharmacies Market by Country
      • 7.4.3.2 LAMEA Retail Pharmacies & Stores Market by Country
      • 7.4.3.3 LAMEA Online Pharmacies Market by Country
    • 7.4.4 LAMEA Opioid Use Disorder (OUD) Market by Country
      • 7.4.4.1 Brazil Opioid Use Disorder (OUD) Market
        • 7.4.4.1.1 Brazil Opioid Use Disorder (OUD) Market by Drug Class
        • 7.4.4.1.2 Brazil Opioid Use Disorder (OUD) Market by Route of Administration
        • 7.4.4.1.3 Brazil Opioid Use Disorder (OUD) Market by Distribution Channel
      • 7.4.4.2 Argentina Opioid Use Disorder (OUD) Market
        • 7.4.4.2.1 Argentina Opioid Use Disorder (OUD) Market by Drug Class
        • 7.4.4.2.2 Argentina Opioid Use Disorder (OUD) Market by Route of Administration
        • 7.4.4.2.3 Argentina Opioid Use Disorder (OUD) Market by Distribution Channel
      • 7.4.4.3 UAE Opioid Use Disorder (OUD) Market
        • 7.4.4.3.1 UAE Opioid Use Disorder (OUD) Market by Drug Class
        • 7.4.4.3.2 UAE Opioid Use Disorder (OUD) Market by Route of Administration
        • 7.4.4.3.3 UAE Opioid Use Disorder (OUD) Market by Distribution Channel
      • 7.4.4.4 Saudi Arabia Opioid Use Disorder (OUD) Market
        • 7.4.4.4.1 Saudi Arabia Opioid Use Disorder (OUD) Market by Drug Class
        • 7.4.4.4.2 Saudi Arabia Opioid Use Disorder (OUD) Market by Route of Administration
        • 7.4.4.4.3 Saudi Arabia Opioid Use Disorder (OUD) Market by Distribution Channel
      • 7.4.4.5 South Africa Opioid Use Disorder (OUD) Market
        • 7.4.4.5.1 South Africa Opioid Use Disorder (OUD) Market by Drug Class
        • 7.4.4.5.2 South Africa Opioid Use Disorder (OUD) Market by Route of Administration
        • 7.4.4.5.3 South Africa Opioid Use Disorder (OUD) Market by Distribution Channel
      • 7.4.4.6 Nigeria Opioid Use Disorder (OUD) Market
        • 7.4.4.6.1 Nigeria Opioid Use Disorder (OUD) Market by Drug Class
        • 7.4.4.6.2 Nigeria Opioid Use Disorder (OUD) Market by Route of Administration
        • 7.4.4.6.3 Nigeria Opioid Use Disorder (OUD) Market by Distribution Channel
      • 7.4.4.7 Rest of LAMEA Opioid Use Disorder (OUD) Market
        • 7.4.4.7.1 Rest of LAMEA Opioid Use Disorder (OUD) Market by Drug Class
        • 7.4.4.7.2 Rest of LAMEA Opioid Use Disorder (OUD) Market by Route of Administration
        • 7.4.4.7.3 Rest of LAMEA Opioid Use Disorder (OUD) Market by Distribution Channel

Chapter 8. Company Profiles

  • 8.1 Indivior PLC (Reckitt Benckiser Group plc)
    • 8.1.1 Company Overview
    • 8.1.2 Financial Analysis
    • 8.1.3 Product and Regional Analysis
    • 8.1.4 Research & Development Expenses
    • 8.1.5 Recent strategies and developments:
      • 8.1.5.1 Partnerships, Collaborations, and Agreements:
      • 8.1.5.2 Acquisition and Mergers:
  • 8.2 Collegium Pharmaceutical, Inc. (BioDelivery Sciences International, Inc.)
    • 8.2.1 Company Overview
    • 8.2.2 Financial Analysis
    • 8.2.3 Research & Development Expenses
  • 8.3 Orexo AB (Orexo US, Inc.)
    • 8.3.1 Company Overview
    • 8.3.2 Financial Analysis
    • 8.3.3 Segmental and Regional Analysis
    • 8.3.4 Research & Development Expenses
    • 8.3.5 Recent strategies and developments:
      • 8.3.5.1 Partnerships, Collaborations, and Agreements:
  • 8.4 Alkermes PLC
    • 8.4.1 Company Overview
    • 8.4.2 Financial Analysis
    • 8.4.3 Regional Analysis
    • 8.4.4 Research & Development Expenses
    • 8.4.5 Recent strategies and developments:
      • 8.4.5.1 Trials and Approvals:
  • 8.5 Titan Pharmaceuticals, Inc.
    • 8.5.1 Company Overview
    • 8.5.2 Financial Analysis
    • 8.5.3 Segmental and Regional Analysis
    • 8.5.4 Research & Development Expenses
    • 8.5.5 Recent strategies and developments:
      • 8.5.5.1 Trials and Approvals:
  • 8.6 Camurus AB
    • 8.6.1 Company Overview
    • 8.6.2 Financial Analysis
    • 8.6.3 Segmental and Regional Analysis
    • 8.6.4 Research & Development Expenses
    • 8.6.5 Recent strategies and developments:
      • 8.6.5.1 Partnerships, Collaborations, and Agreements:
      • 8.6.5.2 Trials and Approvals:
  • 8.7 AstraZeneca PLC
    • 8.7.1 Company Overview
    • 8.7.2 Financial Analysis
    • 8.7.3 Regional Analysis
    • 8.7.4 Research & Development Expenses
    • 8.7.5 Recent strategies and developments:
      • 8.7.5.1 Acquisition and Mergers:
  • 8.8 Hikma Pharmaceuticals PLC
    • 8.8.1 Company Overview
    • 8.8.2 Financial Analysis
    • 8.8.3 Segmental and Regional Analysis
    • 8.8.4 Research & Development Expenses
    • 8.8.5 Recent strategies and developments:
      • 8.8.5.1 Product Launches and Product Expansions:
  • 8.9 Mallinckrodt PLC
    • 8.9.1 Company Overview
    • 8.9.2 Financial Analysis
    • 8.9.3 Segmental and Regional Analysis
    • 8.9.4 Research & Development Expense
  • 8.10. Viatris, Inc.
    • 8.10.1 Company Overview
    • 8.10.2 Financial Analysis
    • 8.10.3 Segmental Analysis
    • 8.10.4 Research & Development Expense
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제